TransMedics Group, Inc. (TMDX) Stock Analysis
Healthcare · Medical Devices
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion,... Read more
TrendMatrix rates TransMedics Group, Inc. (TMDX) as Hold with moderate confidence. The stock trades at $104.80 with +28.5% upside to the $135.07 price target. Overall score: 6.3/10 across 10 analysis dimensions. Reward/risk ratio: 5.6:1.
Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates TransMedics Group, Inc. (TMDX) as Hold with moderate confidence. Score 6.3/10.
Take-profit target: $135.07 (+28.5% upside). Reward/risk ratio: 5.6:1. Stop-loss: $99.72.
Leverage penalty (D/E 1.1): -0.5; Negative momentum; Elevated risk factors.
TransMedics Group, Inc. trades at a P/E of 22.5 (forward 29.7). TrendMatrix value score: 6.2/10. Verdict: Hold.
20 analysts cover TMDX with a consensus score of 4.2/5. Average price target: $159.
What does TransMedics Group, Inc. do?TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant...
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.